MBX Biosciences Reports Q2 Results and Updates Pipeline
MBX Biosciences reported Q2 results highlighting progress on canvuparatide and MBX 4291 in the obesity pipeline with a robust cash balance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day